KFH - OAKLAND
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $24.4M
- Transactions
- 1,939
- Companies
- 40
- Average per transaction
- $12,600
Who reported the payments
| Edwards Lifesciences | $4,786,899 |
| Merck | $4,750,756 |
| Gilead | $4,012,489 |
| Bristol Myers Squibb | $2,040,703 |
| Amarin Pharma, Inc. | $2,015,612 |
| Seagen Inc. | $1,369,358 |
| E.r. Squibb & Sons, L.L.C. | $1,060,828 |
| Jazz Pharmaceuticals Inc. | $784,927 |
| Esperion Therapeutics, Inc. | $518,750 |
| Sun Pharmaceutical Industries Inc. | $360,829 |
| Genentech, Inc. | $349,131 |
| Incyte Corporation | $195,482 |
| Novartis | $187,183 |
| F. Hoffmann-la Roche AG | $183,581 |
| Daiichi Sankyo Inc. | $159,686 |
| Janssen Scientific Affairs, LLC | $139,551 |
| ADC Therapeutics America, Inc. | $119,587 |
| Mallinckrodt Enterprises LLC | $119,449 |
| Nevro Corp. | $108,002 |
| Chiesi USA, Inc. | $97,437 |
| Puma Biotechnology, Inc. | $96,669 |
| Intercept Pharmaceuticals, Inc. | $93,510 |
| Sanofi US Services Inc. | $78,562 |
| Novocure Inc. | $71,441 |
| Mirati Therapeutics, Inc. | $67,534 |
| United Therapeutics Corporation | $60,803 |
| Johnson & Johnson | $59,614 |
| Takeda Pharmaceuticals U.S.A., Inc. | $53,555 |
| Exact Sciences | $50,000 |
| W. L. Gore & Associates, Inc. | $50,000 |
| Astellas Pharma Global Development | $46,000 |
| Alnylam Pharmaceuticals Inc. | $43,000 |
| CSL Behring | $38,582 |
| Surgalign Spine Technologies, Inc. | $33,824 |
| MDD US Operations, LLC | $31,979 |
| Microvention, Inc. | $31,929 |
| Genmab A/s | $31,915 |
| Atricure, Inc. | $30,000 |
| Boston Scientific | $18,224 |
| Janssen Research & Development, LLC | $15,556 |